Abstract
Protein kinases are important enzymes in solid tumour and leukaemia pathologies. Their structures are well understood at the atomic level and their key role in the progression of certain cancers makes them valuable targets for anti-cancer therapy. Through medicinal chemical approaches, we developed an efficient preparative stereospecific synthesis of N12, N13 pyran-bridged indolocarbazoles that opens access to functional diversity within this previously challenging series. We focused upon the indolocarbazole class of chemical inhibitors, which includes S27888, an inhibitor we previously identified. We used biochemical and cell-based assays to identify small molecule inhibitors of Checkpoint kinase 1 (Chk1), a serine/threonine protein kinase that is activated when cancer cells are treated with genotoxic agents. These compounds show a promising inhibitory profile on Chk1. Furthermore, these compounds are active against FLT3, which is a tyrosine kinase that is frequently activated in human leukaemias. These data suggest that this chemical class may provide a source of therapeutic compounds for a broad range of human cancers.
Keywords: Checkpoint kinase 1, Chk1, FLT3, Checkpoint adaptation, Genotoxic agents, HT29 cells, Indolocarbazoles, Protein kinases, Stereospecific synthesis, antiproliferative properties
Anti-Cancer Agents in Medicinal Chemistry
Title: Synthesis of Cis-Fused Pyran Indolocarbazole Derivatives that Inhibit FLT3 Kinase and the DNA Damage Kinase, Checkpoint Kinase 1
Volume: 12 Issue: 3
Author(s): Francoise M. Perron-Sierra, Nathalie Kucharkzyk, Celine Boucley, Christel Guyard-Daumas, Sophie Sciberras, Christine Fouache, Sabine Plantier, Aurelie Studeny, Celine Bossard, Patrick J. Casara and Roy M. Golsteyn
Affiliation:
Keywords: Checkpoint kinase 1, Chk1, FLT3, Checkpoint adaptation, Genotoxic agents, HT29 cells, Indolocarbazoles, Protein kinases, Stereospecific synthesis, antiproliferative properties
Abstract: Protein kinases are important enzymes in solid tumour and leukaemia pathologies. Their structures are well understood at the atomic level and their key role in the progression of certain cancers makes them valuable targets for anti-cancer therapy. Through medicinal chemical approaches, we developed an efficient preparative stereospecific synthesis of N12, N13 pyran-bridged indolocarbazoles that opens access to functional diversity within this previously challenging series. We focused upon the indolocarbazole class of chemical inhibitors, which includes S27888, an inhibitor we previously identified. We used biochemical and cell-based assays to identify small molecule inhibitors of Checkpoint kinase 1 (Chk1), a serine/threonine protein kinase that is activated when cancer cells are treated with genotoxic agents. These compounds show a promising inhibitory profile on Chk1. Furthermore, these compounds are active against FLT3, which is a tyrosine kinase that is frequently activated in human leukaemias. These data suggest that this chemical class may provide a source of therapeutic compounds for a broad range of human cancers.
Export Options
About this article
Cite this article as:
M. Perron-Sierra Francoise, Kucharkzyk Nathalie, Boucley Celine, Guyard-Daumas Christel, Sciberras Sophie, Fouache Christine, Plantier Sabine, Studeny Aurelie, Bossard Celine, J. Casara Patrick and M. Golsteyn Roy, Synthesis of Cis-Fused Pyran Indolocarbazole Derivatives that Inhibit FLT3 Kinase and the DNA Damage Kinase, Checkpoint Kinase 1, Anti-Cancer Agents in Medicinal Chemistry 2012; 12 (3) . https://dx.doi.org/10.2174/187152012800228823
DOI https://dx.doi.org/10.2174/187152012800228823 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Signaling in Human B-Lymphoma Rafts
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Oncogenic Fusion Tyrosine Kinases as Molecular Targets for Anti-Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Global Gene Expression in Classification, Pathogenetic Understanding and Identification of Therapeutic Targets in Acute Myeloid Leukemia
Current Pharmaceutical Biotechnology Lumiflavin Enhances the Effects of Ionising Radiation on Ovarian Cancer Stem-Like Cells by Inhibiting Autophagy
Anti-Cancer Agents in Medicinal Chemistry Tartrate-Resistant Acid Phosphatase: A Target for Anti-Osteoporotic Chemotherapeutics
Current Enzyme Inhibition The Application of Fungal Beta-glucans for the Treatment of Colon Cancer
Anti-Cancer Agents in Medicinal Chemistry Synthetic Peptides As Non-Viral DNA Vectors
Current Gene Therapy Protein Kinase B/AKT and Focal Adhesion Kinase: Two Close Signaling Partners in Cancer
Anti-Cancer Agents in Medicinal Chemistry Ag+ Complexes as Potential Therapeutic Agents in Medicine and Pharmacy
Current Medicinal Chemistry The Role of STAT3 Signaling in Mediating Tumor Resistance to Cancer Therapy
Current Drug Targets Biologics for ANCA-Associated Vasculitis
Inflammation & Allergy - Drug Targets (Discontinued) Use of Complementary Medicine Amongst Patients on Antiretroviral Drugs in an HIV Treatment Centre in Lagos, Nigeria
Current Drug Safety Matrix Metalloproteinases
Current Medicinal Chemistry Bortezomib and Arsenious Acid Synergistically Inhibit HL-60 Cells Viability in vitro and in vivo
Current Signal Transduction Therapy Neuroimaging of Non-Accidental Injury
Current Pediatric Reviews On the Origin of Epidermal Cancers
Current Molecular Medicine Molecular Targeting of Protein Kinases to Optimize Selectivity and Resistance Profiles of Kinase Inhibitors
Current Topics in Medicinal Chemistry New Therapies in SLE
Recent Patents on Inflammation & Allergy Drug Discovery Sirtuin Modulators: Mechanisms and Potential Clinical Implications
Current Medicinal Chemistry Characterization of Molecular and Functional Alterations of Tumor Endothelial Cells to Design Anti-Angiogenic Strategies
Current Vascular Pharmacology